{"organizations": [], "uuid": "134d6551232ccc5ad0cc2b5f18142b054e53bf4c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180329.html", "section_title": "Archive News &amp; Video for Thursday, 29 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/pfizer-study/pfizers-rare-disease-drug-succeeds-in-late-stage-study-idUSL3N1RB5YE", "country": "US", "domain_rank": 408, "title": "Pfizer's rare disease drug succeeds in late-stage study", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.413, "site_type": "news", "published": "2018-03-30T01:06:00.000+03:00", "replies_count": 0, "uuid": "134d6551232ccc5ad0cc2b5f18142b054e53bf4c"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/pfizer-study/pfizers-rare-disease-drug-succeeds-in-late-stage-study-idUSL3N1RB5YE", "ord_in_thread": 0, "title": "Pfizer's rare disease drug succeeds in late-stage study", "locations": [], "entities": {"persons": [{"name": "akankshita mukhopadhyay", "sentiment": "none"}, {"name": "shounak dasgupta", "sentiment": "none"}], "locations": [{"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "pfizer", "sentiment": "negative"}, {"name": "pfizer inc", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 29 (Reuters) - Pfizer Inc said on Thursday its drug for a rare and fatal disease associated with progressive heart failure met the main goal in a late-stage study.\nThe company said the drug, tafamidis, showed statistically significant reduction in deaths and frequency of cardiovascular-related hospitalizations compared to a placebo at 30 months. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Shounak Dasgupta)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-03-30T01:06:00.000+03:00", "crawled": "2018-03-30T12:47:12.002+03:00", "highlightTitle": ""}